ClinicalTrials.gg
CompletedNCT00778830APECUpdated May 14, 2015Results posted

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

A Phase 1/2 interventional study of Cetuximab and FOLFIRI in Metastatic Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-14.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
289
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.

Enrollment
11th of 37
289 · median 102
Started
2009
with 4 others
Phase 1/2
4 of 37
2 open now
Registered
7th of 37
by date

Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 11th largest by enrollment, is one of 5 that started in 2009, is one of 4 in phase 1/2, and was the 7th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Folfox protocol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing Folfox protocol in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer.

Only subjects with k-ras oncogene (KRAS) wild-type tumors are eligible. Efficacy will be assessed every 8 weeks. Treatment will be continued until progressive disease or unacceptable adverse events occur. After the end of study treatment, information on further anticancer treatment and survival will be collected every 3 months.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • mCRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Signed written

  • Inpatient or outpatient subjects, 18 years of age
  • Diagnosis of confirmed adenocarcinoma of the colon or rectum
  • disease (M1)
  • of at least 12 weeks
  • Presence of at least 1 measurable index lesion (not lie in an irradiated area) by computed tomography (CT) scan or magnetic resonance imaging (MRI)
  • (ECOG) performance status of 0 or 1 at study entry
  • Effective for both male and female subjects if the risk of conception exists
  • White blood cell count greater than or equal to (>=) 3,000 per cubic millimeter (/mm\^3) with neutrophils >=1,500/mm3, count >=100,000/mm3, >=5.6 millimole per liter (mmol/L) (9 gram per deciliter [g/dL])
  • Total less than or equal to (\<=) 1.5 x upper reference range
  • (AST) \<=2.5 x upper reference range, or \<=5 x upper reference range in case of liver metastasis
  • Serum creatinine \<=1.5 x upper reference range
  • Recovery from relevant toxicity to previous treatment before study entry
  • KRAS wild-type status of tumor tissue

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for colorectal cancer except treatment if terminated >6 months before the start of treatment in this study
  • Radiotherapy, surgery (excluding prior diagnostic ) or any drug in the 30 days before the start of treatment in this study
  • Concurrent chronic systemic immune therapy, targeted therapy, anti-vascular endothelial growth factor (VEGF) therapy, or epidermal growth factor receptor (EGFR-) pathway targeting therapy not indicated in this study protocol
  • Concurrent hormone therapy not indicated in this study protocol except for physiologic replacement or
  • Known reaction to any of the components of study treatments
  • Pregnancy (absence to be confirmed by beta human choriongonadotrophin [beta-hCG] test) or lactation period
  • and/or (known or suspected)
  • coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
  • Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
  • Peripheral neuropathy > grade 1
  • Previous other than colorectal cancer in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix
  • Known alcohol or drug abuse
  • Medical or psychological conditions that would not permit the patient to complete the study or sign
  • Participation in another clinical study within the past 30 days
  • Significant disease which, in the investigator's opinion, would exclude the patient from the study
  • Legal incapacity or limited legal capacity
  • KRAS mutated status of tumor tissue
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    Cetuximab plus FOLFIRI

    Drug: Cetuximab · Drug: FOLFIRI

  • Experimental
    Cetuximab plus FOLFOX

    Drug: Cetuximab · Drug: FOLFOX

Interventions

  • Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.

    Also known as: Erbitux

  • DrugFOLFIRI

    Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.

  • DrugFOLFOX

    Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Best Overall Confirmed Response Rate (BORR)

    Response rate was defined as the percentage of subjects with BORR (confirmed complete response \[CR\] or partial response \[PR\]) according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) criteria. As per RECIST v 1.0 criteria for target lesions and assessed by magnetic resonance imaging (MRI): CR = disappearance of all target lesions; PR = at least 30 percent (%) decrease in the sum of the longest diameter of target lesions. Response rate will be assessed every 8 weeks.

    Time frame: From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited until data cut-off date (31 May 2012)

Secondary outcomes

  1. Progression-Free Survival (PFS) Time

    PFS time was defined as the time from first administration of study drug until first observation of disease progression or death when death occurs within 90 days of the last tumor assessment or first study drug dose whichever occurred.

    Time frame: From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited and until data cut-off date (31 March 2014)

  2. Overall Survival (OS) Time

    OS time was defined as the time from first administration of study drug until date of death, assessed up to 5 years. OS time was censored if the subject was found to be alive on the last date of the assessment.

    Time frame: From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited and until data cut-off date (31 March 2014)

  3. Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death

    An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited and until data cut-off date (31 March 2014)

07

Results

Posted May 14, 2015

Participant flow

First/Last subject (informed consent): February 2009/June 2012. Study completion date: April 2014. Clinical data cut-off: 31 March 2014. Subjects were recruited in 12 countries (Australia, China, Hong Kong, India, Indonesia, Korea, Malaysia, Singapore, Pakistan, Philippines, Taiwan and Thailand) across the globe in 43 centers.

Participant flow — Overall Study
MilestoneCetuximab Plus FOLFIRICetuximab Plus FOLFOX
Started101188
Completed101187
Not completed01
Withdrew: Ongoing at data cut-off01

Outcome measures

PrimaryPercentage of Subjects With Best Overall Confirmed Response Rate (BORR)

Response rate was defined as the percentage of subjects with BORR (confirmed complete response \[CR\] or partial response \[PR\]) according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) criteria. As per RECIST v 1.0 criteria for target lesions and assessed by magnetic resonance imaging (MRI): CR = disappearance of all target lesions; PR = at least 30 percent (%) decrease in the sum of the longest diameter of target lesions. Response rate will be assessed every 8 weeks.

Time frame:
From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited until data cut-off date (31 May 2012)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Best Overall Confirmed Response Rate (BORR)
Percentage of subjectsCetuximab Plus FOLFIRICetuximab Plus FOLFOX
Percentage of Subjects With Best Overall Confirmed Response Rate (BORR)54.561.2
Statistical analysis
  • Cetuximab Plus FOLFIRI vs Cetuximab Plus FOLFOX · Odds ratio (or): 1.3176 · 95% CI 0.8078 to 2.1491
SecondaryProgression-Free Survival (PFS) Time

PFS time was defined as the time from first administration of study drug until first observation of disease progression or death when death occurs within 90 days of the last tumor assessment or first study drug dose whichever occurred.

Time frame:
From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited and until data cut-off date (31 March 2014)
Reported as:
Median · months
Progression-Free Survival (PFS) Time
monthsCetuximab Plus FOLFIRICetuximab Plus FOLFOX
Progression-Free Survival (PFS) Time11.1 (8.1 to 14.8)11.1 (9.0 to 12.7)
SecondaryOverall Survival (OS) Time

OS time was defined as the time from first administration of study drug until date of death, assessed up to 5 years. OS time was censored if the subject was found to be alive on the last date of the assessment.

Time frame:
From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited and until data cut-off date (31 March 2014)
Reported as:
Median · months
Overall Survival (OS) Time
monthsCetuximab Plus FOLFIRICetuximab Plus FOLFOX
Overall Survival (OS) Time26.6 (21.5 to 33.8)27.0 (22.8 to 30.1)
SecondaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death

An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the start of the trial until disease progression, death or last tumor assessment, reported between day of first subject recruited and until data cut-off date (31 March 2014)
Reported as:
Number · Subjects
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death
SubjectsCetuximab Plus FOLFIRICetuximab Plus FOLFOX
TEAEs99180
Treatment Emergent SAEs3764
TEAEs Leading to Death510
TEAEs Leading to Discontinuation00

Adverse events

Collected over From the start of the trial treatment up to the data cut-off date (31 March 2014). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab Plus FOLFIRI—37/101 (36.6%)93/101 (92.1%)
Cetuximab Plus FOLFOX—64/188 (34%)177/188 (94.1%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventCetuximab Plus FOLFIRICetuximab Plus FOLFOX
Intestinal obstructionGastrointestinal disorders5/1012/188
NeutropeniaBlood and lymphatic system disorders4/1013/188
DiarrhoeaGastrointestinal disorders4/1016/188
PyrexiaGeneral disorders3/1017/188
Febrile neutropeniaBlood and lymphatic system disorders2/1016/188
IleusGastrointestinal disorders3/1010/188
HypokalaemiaMetabolism and nutrition disorders3/1014/188
Deep vein thrombosisVascular disorders3/1011/188
VomitingGastrointestinal disorders2/1014/188
ParonychiaInfections and infestations2/1011/188
Most frequent other events
Showing 10 of 58
Most frequent other events
EventCetuximab Plus FOLFIRICetuximab Plus FOLFOX
RashSkin and subcutaneous tissue disorders55/101115/188
NauseaGastrointestinal disorders61/10168/188
DiarrhoeaGastrointestinal disorders58/10179/188
NeutropeniaBlood and lymphatic system disorders53/101100/188
VomitingGastrointestinal disorders37/10163/188
Neuropathy peripheralNervous system disorders4/10163/188
Decreased appetiteMetabolism and nutrition disorders33/10151/188
ParonychiaInfections and infestations32/10148/188
StomatitisGastrointestinal disorders31/10152/188
AlopeciaSkin and subcutaneous tissue disorders30/10117/188

Baseline characteristics

Intention-to-treat (ITT) population consisted of all the enrolled subjects who received at least one dose of study treatment.

Age, Categorical
Age, Categorical(Participants)Cetuximab Plus FOLFIRICetuximab Plus FOLFOXTotal
<=18 years000
Between 18 and 65 years70145215
>=65 years314374
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab Plus FOLFIRICetuximab Plus FOLFOXTotal
Female3569104
Male66119185
08

Study locations

1 site
  • Research Site
    Singapore, Singapore
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2008
First posted
Oct 23, 2008
Start
Feb 2009
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
May 14, 2015
Last update
May 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00778830
Collaborators
Merck Pte. Ltd., Singapore
Responsible party
Sponsor
First posted
Oct 23, 2008
Start date
Feb 2009
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
May 14, 2015
Last update
May 14, 2015

Study contacts

Medical Responsible
study director · Merck Pte. Ltd., Singapore

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Folfox protocol

Start the discussion